Company: CNTB
Filing Date: 2025-06-10
Form Type: F-3
Source: 0001193125-25-138482
Chunk: 79

Company: Connect Biopharma Holdings Ltd
Filing Date: 2025-06-10
Form: F-3
Chunk 79
---
 third parties from commercializing Product Candidates similar or identical to ours would be adversely affected. |

| • |     | The patent protection and patent prosecution for our current or any future Product Candidates may be dependent 
 on third parties.                                                                                              |

| • |     | If we are not successful in obtaining patent term extensions for our current and future Product Candidates,                                                                                                                                       
 our business may be harmed, and the lack of effective enforcement of patent linkage and the absence of patent term extension and data and market exclusivity for Product Candidates approved by the NMPA could increase the risk of early generic 
 competition with our products in the PRC.                                                                                                                                                                                                         |

| • |     | Obtaining and maintaining our patent protection depends on compliance with various procedural, document                                                                                     
 submission, fee payment and other requirements imposed by governmental patent agencies, and our patent protection could be reduced or eliminated for noncompliance with these requirements. |

| • |     | Third-party claims or litigation alleging infringement, misappropriation or other violation of, or seeking to                                                                    
 invalidate, patents or other intellectual and proprietary rights, may delay or prevent the development and commercialization of any of our current or future Product Candidates. |

| • |     | We may not identify relevant third-party patents or may incorrectly interpret the relevance, scope or                      
 expiration of a third-party patent, which might adversely affect our ability to develop and market our Product Candidates. |

| • |     | We may need to acquire or license intellectual property from third parties, and such licenses may not be 
 available or may not be available on commercially reasonable terms.                                      |

| • |     | We may become involved in lawsuits to protect or enforce our patents or other intellectual property rights, 
 which could be expensive, time-consuming and unsuccessful.                                                  |

| • |     | Derivation, interference or other proceedings may be necessary to determine priority of inventions relating to                                                                       
 our current or future Product Candidates, and an unfavorable outcome may require us to cease using the related technology or to attempt to license rights from the prevailing party. |

| • |     | Because of the expense and uncertainty of litigation, we may not be in a position to enforce our intellectual 
 property rights against third parties.                                                                        |

| • |     | Patent reform legislation could increase the uncertainties and costs surrounding the prosecution of our                                                                           
 current and future patent applications or those of our future licensors and the enforcement or defense of our current and future issued patents or those of our future licensors. |

7

| • |     | Changes in U.S